Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John O'Neill who wrote (17494)	3/16/1998 11:36:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

John, Actually, the IMNX news is related to LGND. IMNX is using the injected IL-4 receptor to soak up free IL-4. This approach seems to work in a small number of asthma patients. Of course an injected drug isn't that convenient, and I assume that the cost would be very high. LGND has an IL-4 program that would use a small molecule that would block the signal initiated when IL-4 binds to its receptor. Thus the good news for IMNX is also good news for LGND, demonstrating the blockage of the signal helps relieve symptoms in patients. LGND's compound would be taken oral and could be manufactured and modified very cheaply.